Navigation Links
Frost & Sullivan Lauds Carl Zeiss Meditec for Dominating the OCT Market for Ophthalmic Applications

MOUNTAIN VIEW, Calif., March 31 /PRNewswire/ -- Based on its recent analysis of the optical technologies market, Frost & Sullivan recognizes Carl Zeiss Meditec with the 2009 North American Frost & Sullivan Market Leadership Award for its optical coherence tomography (OCT) technology for ophthalmic applications. Carl Zeiss Meditec is a pioneer of OCT technology and has launched clinical tools that revolutionized the diagnosis and treatment of eye diseases.


Carl Zeiss Meditec was the first to introduce Time Domain (TD) OCT-based innovative products for retinal, anterior segment/cornea, and glaucoma imaging. More recently, the company introduced the next generation of Fourier Domain (FD) OCT-based product line for ophthalmic applications.

"Multiple start-up companies have introduced promising FD OCT-based products, creating an increasingly competitive dynamic," says Frost & Sullivan Senior Research Analyst Madhu Sharma, Ph.D. "Nonetheless, Carl Zeiss Meditec has responded by implementing an innovation-centric strategy focused on continually presenting novel products and thereby, maintaining a dominant market position."

The company's OCT systems are one of the most widely adopted clinical tools among ophthalmologists. The Stratus OCT(TM) and new Cirrus(TM) HD-OCT systems offer proficiencies and streamlined workflows that allow physicians to gather and interpret detailed disease information.

Additionally, the company has developed proprietary image analysis algorithms that provide volumetric data and aid in interpreting three dimensional images in a highly reproducible and quantitative fashion. It continues to invest in upgrading software for objective measurement and subjective clinical evaluation of retinal disease detection. To cement its strong market position, it has also increased spending in optical technology R&D.

Apart from providing advanced imaging capabilities, Carl Zeiss Meditec offers unparalleled customer service. With its innovative technology and excellent support to the end-users, the company has established a very loyal customer-base and continues to expand its presence. It has an outstanding customer care solution organization that recruits highly trained staff to assist customers and provide quality replacement parts and supplies. The company provides in-house technical support and best-in-class email, online and telephone support. In addition, it offers an array of technical training opportunities to facilitate the process of new product adoption.

"Carl Zeiss Meditec received the highest overall Frost & Sullivan Competitive Metrics Score in the recently completed Strategic Analysis of Optical Imaging Technologies in U.S. Clinical Diagnostics Markets," continues Dr. Sharma. "The company's high scores are tied to its success in the OCT Technology segment of the Analysis."

With an overall score of 10.22, Carl Zeiss Meditec received tier I scores in all four categories of 'market positioning and growth,' 'innovative performance,' 'growth strategy,' and 'leveragable assets'. The score break-up is 2.67 for 'market positioning and growth,' 2.33 for 'innovative performance,' and 2.61 for 'growth strategy.' The Company's overall score is over 2.2 points higher than the average of the other participants, which received a combined score of 8.01.

In short, its careful attention to product quality, breadth of product line, excellent customer support, and reputable brand name has earned Carl Zeiss Meditec a leadership position in the OCT technology market for ophthalmic applications.

Each year, Frost & Sullivan presents this award to the company that has exhibited market share leadership by excelling in all areas of the market leadership process, including the identification of market challenges, drivers and restraints, as well as strategy development and methods of addressing market dynamics. Furthermore, the Award recipient has continually demonstrated solutions for monitoring market changes and implementing superior market strategies.

Frost & Sullivan's Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About Carl Zeiss Meditec

Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of the German stock exchange, is one of the world's leading medical technology companies.

The Company supplies innovative technologies and application-oriented solutions which enable doctors to improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat ophthalmic diseases. In the field of Neuro/ENT surgery the Company provides innovative visualization solutions. Carl Zeiss Meditec's medical technology portfolio is rounded off by promising future technologies such as intraoperative radiotherapy.

The Company's around 2,100 employees generated revenue of about EUR 600 million in fiscal year 2007/08 (ended Sept. 30). The headquarters of Carl Zeiss Meditec are located in Jena, Germany. In addition to other subsidiaries in Germany, the Company is represented by over 50 percent of its employees at sites in the USA, Japan, Spain and France.

Thirty-five percent of Carl Zeiss Meditec's shares are in free float. The remaining 65 percent are held by Carl Zeiss AG, one of the world's leading groups engaged in the optical and opto-electronics industry. The five independently run business segments of Carl Zeiss AG operate in the future-oriented markets "Medical and Research Solutions", "Industrial Solutions" and "Lifestyle Products". Carl Zeiss AG is headquartered in Oberkochen, Germany. During fiscal year 2007/08 (ended Sept. 30) the company generated revenues of about EUR 2.7 billion. Carl Zeiss has around 13,000 employees in more than 30 countries, including more than 8,000 in Germany.

For further information please visit our website at:

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 31 offices on six continents. To join our Growth Partnership, please visit

    Jake Wengroff

SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Frost & Sullivan Hosts Presentation on MicroRNAs: From Stem Cells and Cancer to Diagnostics and Therapeutics
2. Frost & Sullivan Award Highlights Opportunity for Main Street Biotech
3. Frost & Sullivan Recognizes Life Technologies for Excellence in the Life Science Research Tools Industry
4. Frost & Sullivan Recognizes Excellence in Medical Technologies & Life Sciences
5. Frost & Sullivan Recognizes Nanopoint for its Pioneering Cell Imaging Solution, the cellTRAY(R) Imaging System CT-2000
6. Frost & Sullivan: In Vitro Diagnostics Market
7. Frost & Sullivan Recognizes Novagali Pharma for Innovation in Ophthalmic Therapies
8. Frost & Sullivan European Drug Discovery Product Innovation Award Bestowed on Xenometrix AG
9. Frost & Sullivan Recognizes ApaTechs Leadership in Orthopedic Biologics
10. The Need for Safe and Affordable Biopharmaceuticals Drives the Development of the European Biosimilars Market, Says Frost & Sullivan
11. Magellan to Receive Frost & Sullivan 2009 North American Product Innovation Award; Three-Minute LeadCare(R) II Test Identifies Children with Lead Poisoning
Post Your Comments:
(Date:11/24/2015)... Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at ... on Wednesday, December 2 at 9:30 a.m. ET/6:30 a.m. PT ... provide a corporate overview. th Annual Oppenheimer Healthcare ... ET/10:00 a.m. PT . Jim Mazzola , vice president ... --> th Annual Oppenheimer Healthcare Conference in ...
(Date:11/24/2015)... 2015  Clintrax Global, Inc., a worldwide provider of clinical research ... announced that the company has set a new quarterly earnings record ... quarter growth posted for Q3 of 2014 to Q3 of 2015. ... Mexico , with the establishment of an Asia-Pacific ... United Kingdom and Mexico ...
(Date:11/24/2015)... --> --> ... by Transparency Market Research, the global non-invasive prenatal testing ... 17.5% during the period between 2014 and 2022. The ... Analysis, Size, Volume, Share, Growth, Trends and Forecast 2014 ... to reach a valuation of US$2.38 bn by 2022. ...
(Date:11/24/2015)... , ... November 24, 2015 , ... InSphero AG, the ... cell culture models, has promoted Melanie Aregger to serve as Chief Operating Officer. ... served on the management team and was promoted to Head of InSphero ...
Breaking Biology Technology:
(Date:11/9/2015)... , Nov. 09, 2015 ... the addition of the "Global Law ... their offering. --> ) ... "Global Law Enforcement Biometrics Market 2015-2019" ... Research and Markets ( ) has ...
(Date:11/4/2015)... 2015 --> ... by Transparency Market Research "Home Security Solutions Market - Global ... - 2022", the global home security solutions market is expected to ... The market is estimated to expand at a CAGR ... 2022. Rising security needs among customers at homes, the ...
(Date:10/29/2015)... , Oct. 29, 2015   MedNet Solutions ... the entire spectrum of clinical research, is pleased to ... High Tech Association (MHTA) as one of only three ... the "Software – Small and Growing" category. The Tekne Awards ... who have shown superior technology innovation and leadership. ...
Breaking Biology News(10 mins):